JNJ-26990990 is a broad-spectrum anticonvulsant drug and a second-generation follow-up to the marketed drug topiramate. It offers the same anticonvulsant effects as topiramate but without the side effects associated with topiramates carbonic anhydrase inhibition. Additionally, JNJ-26990990 has potential use in treating inflammatory pain, neuropathic pain, and depression. [It] entered phase II clinical trials in October 2007.
Molecular Weight:
242.32
Purity:
97.37%
CAS Number:
[877316-38-6]
Formula:
C9H10N2O2S2
Target:
Others|||Calcium Channel|||Sodium Channel
T27673
* VAT and and shipping costs not included. Errors and price changes excepted